CA2640652A1 — Novel coumarin derivative having antitumor activity
Assigned to Chugai Pharmaceutical Co Ltd · Expires 2007-08-16 · 19y expired
What this patent protects
The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: (see formula 1) wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from -N= etc., Y3 and Y4 are selected from -CH= etc., A is selecte…
USPTO Abstract
The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: (see formula 1) wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from -N= etc., Y3 and Y4 are selected from -CH= etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.